{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:14:22Z","timestamp":1787314462335,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T00:00:00Z","timestamp":1709510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T00:00:00Z","timestamp":1709510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s00115-024-01627-3","type":"journal-article","created":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T10:01:41Z","timestamp":1709546501000},"page":"407-415","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Therapieresistenz bei Angsterkrankungen\u00a0\u2013 Definition und Behandlungsoptionen","Treatment resistance in anxiety disorders\u2014Definition and treatment options"],"prefix":"10.1007","volume":"95","author":[{"given":"Katharina","family":"Domschke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Str\u00f6hle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Zwanzger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,4]]},"reference":[{"key":"1627_CR1","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/wps.21078","volume":"22","author":"A Abi-Dargham","year":"2023","unstructured":"Abi-Dargham\u00a0A, Moeller\u00a0SJ, Ali\u00a0F et\u00a0al (2023) Candidate biomarkers in psychiatric disorders: state of the field. World Psychiatry 22:236\u2013262","journal-title":"World Psychiatry"},{"key":"1627_CR2","unstructured":"Bandelow B, Aden I, Alpers GW et\u00a0al (2021) S3-Leitlinie Behandlung von Angstst\u00f6rungen \u2013 Version\u00a02. AWMF. https:\/\/register.awmf.org\/de\/leitlinien\/detail\/051-028"},{"key":"1627_CR3","doi-asserted-by":"crossref","first-page":"93","DOI":"10.31887\/DCNS.2017.19.2\/bbandelow","volume":"19","author":"B Bandelow","year":"2017","unstructured":"Bandelow\u00a0B, Michaelis\u00a0S, Wedekind\u00a0D (2017) Treatment of anxiety disorders. Dialogues Clin Neurosci 19:93\u2013107","journal-title":"Dialogues Clin Neurosci"},{"key":"1627_CR4","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s001150050484","volume":"70","author":"M Bauer","year":"1999","unstructured":"Bauer\u00a0M, Str\u00f6hle\u00a0A (1999) Behandlungsstrategien bei prophylaxeresistenten bipolaren St\u00f6rungen. Nervenarzt 70:587\u2013599","journal-title":"Nervenarzt"},{"key":"1627_CR5","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1017\/S0033291713003243","volume":"44","author":"AJ Baxter","year":"2014","unstructured":"Baxter\u00a0AJ, Vos\u00a0T, Scott\u00a0KM et\u00a0al (2014) The global burden of anxiety disorders in 2010. Psychol Med 44:2363\u20132374","journal-title":"Psychol Med"},{"key":"1627_CR6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jpsychires.2018.03.001","volume":"101","author":"S Bischoff","year":"2018","unstructured":"Bischoff\u00a0S, Wieder\u00a0G, Einsle\u00a0F et\u00a0al (2018) Running for extinction? Aerobic exercise as an augmentation of exposure therapy in panic disorder with agoraphobia. J\u00a0Psychiatr Res 101:34\u201341","journal-title":"J Psychiatr Res"},{"key":"1627_CR7","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S2215-0366(19)30401-8","volume":"6","author":"N Black","year":"2019","unstructured":"Black\u00a0N, Stockings\u00a0E, Campbell\u00a0G et\u00a0al (2019) Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a\u00a0systematic review and meta-analysis. Lancet Psychiatry 6:995\u20131010","journal-title":"Lancet Psychiatry"},{"key":"1627_CR8","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/da.22895","volume":"36","author":"WA Bokma","year":"2019","unstructured":"Bokma\u00a0WA, Wetzer\u00a0G, Gehrels\u00a0JB et\u00a0al (2019) Aligning the many definitions of treatment resistance in anxiety disorders: a\u00a0systematic review. Depress Anxiety 36:801\u2013812","journal-title":"Depress Anxiety"},{"key":"1627_CR9","doi-asserted-by":"crossref","first-page":"109924","DOI":"10.1016\/j.pnpbp.2020.109924","volume":"101","author":"RC Bosman","year":"2020","unstructured":"Bosman\u00a0RC, van Balkom\u00a0A, Rhebergen\u00a0D et\u00a0al (2020) Predicting the course of anxiety disorders: the role of biological parameters. Prog Neuropsychopharmacol Biol Psychiatry 101:109924","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1627_CR10","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/sj.mp.4001852","volume":"11","author":"A Bystritsky","year":"2006","unstructured":"Bystritsky\u00a0A (2006) Treatment-resistant anxiety disorders. Mol Psychiatry 11:805\u2013814","journal-title":"Mol Psychiatry"},{"key":"1627_CR11","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jad.2022.05.008","volume":"310","author":"E Caletti","year":"2022","unstructured":"Caletti\u00a0E, Massimo\u00a0C, Magliocca\u00a0S et\u00a0al (2022) The role of the acceptance and commitment therapy in the treatment of social anxiety: an updated scoping review. J\u00a0Affect Disord 310:174\u2013182","journal-title":"J Affect Disord"},{"key":"1627_CR12","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3390\/brainsci9070164","volume":"9","author":"JK Carpenter","year":"2019","unstructured":"Carpenter\u00a0JK, Pinaire\u00a0M, Hofmann\u00a0SG (2019) From extinction learning to anxiety treatment: mind the gap. Brain Sci 9:164","journal-title":"Brain Sci"},{"key":"1627_CR13","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.pnpbp.2016.02.001","volume":"70","author":"MH Chen","year":"2016","unstructured":"Chen\u00a0MH, Tsai\u00a0SJ (2016) Treatment-resistant panic disorder: clinical significance, concept and management. Prog Neuropsychopharmacol Biol Psychiatry 70:219\u2013226","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"Suppl 2","key":"1627_CR14","doi-asserted-by":"crossref","first-page":"S127","DOI":"10.1007\/s00406-010-0143-9","volume":"260","author":"J Diemer","year":"2010","unstructured":"Diemer\u00a0J, Vennewald\u00a0N, Domschke\u00a0K et\u00a0al (2010) Therapy-refractory panic: current research areas as possible perspectives in the treatment of anxiety. Eur Arch Psychiatry Clin Neurosci 260(Suppl 2):S127\u2013S131","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1627_CR15","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/wps.21177","volume":"23","author":"K Domschke","year":"2024","unstructured":"Domschke\u00a0K, Seuling\u00a0PD, Schiele\u00a0MA et\u00a0al (2024) The definition of treatment resistance in anxiety disorders: a\u00a0Delphi method-based consensus guideline. World Psychiatry 23:113\u2013123","journal-title":"World Psychiatry"},{"key":"1627_CR16","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1517\/14656566.2016.1109628","volume":"17","author":"RC Freire","year":"2016","unstructured":"Freire\u00a0RC, Zugliani\u00a0MM, Garcia\u00a0RF et\u00a0al (2016) Treatment-resistant panic disorder: a\u00a0systematic review. Expert Opin Pharmacother 17:159\u2013168","journal-title":"Expert Opin Pharmacother"},{"key":"1627_CR17","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/da.22337","volume":"32","author":"K Gaudlitz","year":"2015","unstructured":"Gaudlitz\u00a0K, Plag\u00a0J, Dimeo\u00a0F et\u00a0al (2015) Aerobic exercise training facilitates the effectiveness of cognitive behavioral therapy in panic disorder. Depress Anxiety 32:221\u2013228","journal-title":"Depress Anxiety"},{"key":"1627_CR18","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S2215-0366(21)00395-3","volume":"9","author":"GBD 2019 Mental Disorders Collaborators","year":"2022","unstructured":"GBD 2019 Mental Disorders Collaborators (2022) Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990\u20132019: a\u00a0systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry 9:137\u2013150","journal-title":"Lancet Psychiatry"},{"key":"1627_CR19","doi-asserted-by":"crossref","first-page":"101810","DOI":"10.1016\/j.cpr.2019.101810","volume":"75","author":"AT Gloster","year":"2020","unstructured":"Gloster\u00a0AT, Rinner\u00a0MTB, Ioannou\u00a0M et\u00a0al (2020) Treating treatment non-responders: a\u00a0meta-analysis of randomized controlled psychotherapy trials. Clin Psychol Rev 75:101810","journal-title":"Clin Psychol Rev"},{"key":"1627_CR20","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000370162","volume":"84","author":"AT Gloster","year":"2015","unstructured":"Gloster\u00a0AT, Sonntag\u00a0R, Hoyer\u00a0J et\u00a0al (2015) Treating treatment-resistant patients with panic disorder and agoraphobia using psychotherapy: a\u00a0randomized controlled switching trial. Psychother Psychosom 84:100\u2013109","journal-title":"Psychother Psychosom"},{"key":"1627_CR21","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/0269881119874457","volume":"34","author":"P Glue","year":"2020","unstructured":"Glue\u00a0P, Neehoff\u00a0S, Sabadel\u00a0A et\u00a0al (2020) Effects of ketamine in patients with treatment-refractory generalized anxiety and social anxiety disorders: exploratory double-blind psychoactive-controlled replication study. J\u00a0Psychopharmacol 34:267\u2013272","journal-title":"J Psychopharmacol"},{"key":"1627_CR22","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1001\/jamapsychiatry.2022.3679","volume":"80","author":"EA Hoge","year":"2023","unstructured":"Hoge\u00a0EA, Bui\u00a0E, Mete\u00a0M et\u00a0al (2023) Mindfulness-based stress reduction vs escitalopram for the treatment of adults with anxiety disorders: a\u00a0randomized clinical trial. JAMA Psychiatry 80:13\u201321","journal-title":"JAMA Psychiatry"},{"key":"1627_CR23","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/mpr.1359","volume":"21","author":"RC Kessler","year":"2012","unstructured":"Kessler\u00a0RC, Petukhova\u00a0M, Sampson\u00a0NA et\u00a0al (2012) Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psych Res 21:169\u2013184","journal-title":"Int J Methods Psych Res"},{"key":"1627_CR24","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cpr.2015.08.004","volume":"42","author":"AG Loerinc","year":"2015","unstructured":"Loerinc\u00a0AG, Meuret\u00a0AE, Twohig\u00a0MP et\u00a0al (2015) Response rates for CBT for anxiety disorders: need for standardized criteria. Clin Psychol Rev 42:72\u201382","journal-title":"Clin Psychol Rev"},{"key":"1627_CR25","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1001\/jamapsychiatry.2016.3955","volume":"74","author":"D Mataix-Cols","year":"2017","unstructured":"Mataix-Cols\u00a0D, Fern\u00e1ndez de la Cruz\u00a0L, Monzani\u00a0B et\u00a0al (2017) D\u2011Cycloserine augmentation of exposure-based cognitive behavior therapy for anxiety, obsessive-compulsive, and posttraumatic stress disorders: a\u00a0systematic review and meta-analysis of individual participant data. JAMA Psychiatry 74:501\u2013510","journal-title":"JAMA Psychiatry"},{"key":"1627_CR26","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jpsychires.2016.01.011","volume":"75","author":"RC Moore","year":"2016","unstructured":"Moore\u00a0RC, Depp\u00a0CA, Wetherell\u00a0JL et\u00a0al (2016) Ecological momentary assessment versus standard assessment instruments for measuring mindfulness, depressed mood, and anxiety among older adults. J\u00a0Psychiatr Res 75:116\u2013123","journal-title":"J Psychiatr Res"},{"key":"1627_CR27","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1468-1331.2011.03590.x","volume":"19","author":"J Olesen","year":"2012","unstructured":"Olesen\u00a0J, Gustavsson\u00a0A, Svensson\u00a0M et\u00a0al (2012) The economic cost of brain disorders in Europe. Eur J Neurol 19:155\u2013162","journal-title":"Eur J Neurol"},{"key":"1627_CR28","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(21)00359-7","volume":"397","author":"BW Penninx","year":"2021","unstructured":"Penninx\u00a0BW, Pine\u00a0DS, Holmes\u00a0EA et\u00a0al (2021) Anxiety disorders. Lancet 397:914\u2013927","journal-title":"Lancet"},{"key":"1627_CR29","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.beth.2018.07.003","volume":"50","author":"A Pittig","year":"2019","unstructured":"Pittig\u00a0A, Kotter\u00a0R, Hoyer\u00a0J (2019) The struggle of behavioral therapists with exposure: self-reported practicability, negative beliefs, and therapist distress about exposure-based interventions. Behav Ther 50:353\u2013366","journal-title":"Behav Ther"},{"key":"1627_CR30","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1038\/s41380-023-01998-0","volume":"28","author":"K Roseberry","year":"2023","unstructured":"Roseberry\u00a0K, Le-Niculescu\u00a0H, Levey\u00a0DF et\u00a0al (2023) Towards precision medicine for anxiety disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs. Mol Psychiatry 28:2894\u20132912","journal-title":"Mol Psychiatry"},{"key":"1627_CR31","doi-asserted-by":"crossref","first-page":"191","DOI":"10.31887\/DCNS.2015.17.2\/proybyrne","volume":"17","author":"P Roy-Byrne","year":"2015","unstructured":"Roy-Byrne\u00a0P (2015) Treatment-refractory anxiety; definition, risk factors, and treatment challenges. Dialogues Clin Neurosci 17:191\u2013206","journal-title":"Dialogues Clin Neurosci"},{"key":"1627_CR32","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.cbpra.2006.04.020","volume":"14","author":"WC Sanderson","year":"2007","unstructured":"Sanderson\u00a0WC, Bruce\u00a0TJ (2007) Causes and management of treatment-resistant panic disorder and agoraphobia: a\u00a0survey of expert therapists. Cogn Behav Pract 14:26\u201335","journal-title":"Cogn Behav Pract"},{"key":"1627_CR33","doi-asserted-by":"crossref","first-page":"107402","DOI":"10.1016\/j.pharmthera.2019.107402","volume":"204","author":"SB Sartori","year":"2019","unstructured":"Sartori\u00a0SB, Singewald\u00a0N (2019) Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders. Pharmacol Ther 204:107402","journal-title":"Pharmacol Ther"},{"key":"1627_CR34","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jad.2021.08.108","volume":"295","author":"EC Solis","year":"2021","unstructured":"Solis\u00a0EC, van Hemert\u00a0AM, Carlier\u00a0IVE et\u00a0al (2021) The 9\u2011year clinical course of depressive and anxiety disorders: new NESDA findings. J\u00a0Affect Disord 295:1269\u20131279","journal-title":"J Affect Disord"},{"key":"1627_CR35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cpr.2018.03.002","volume":"61","author":"KS Springer","year":"2018","unstructured":"Springer\u00a0KS, Levy\u00a0HC, Tolin\u00a0DF (2018) Remission in CBT for adult anxiety disorders: a\u00a0meta-analysis. Clin Psychol Rev 61:1\u20138","journal-title":"Clin Psychol Rev"},{"key":"1627_CR36","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1007\/s00115-022-01342-x","volume":"93","author":"A Str\u00f6hle","year":"2022","unstructured":"Str\u00f6hle\u00a0A, Bendau\u00a0A, Augustin\u00a0N et\u00a0al (2022) Sports psychiatry and psychotherapy. Nervenarzt 93:742\u2013753","journal-title":"Nervenarzt"},{"key":"1627_CR37","first-page":"611","volume":"155","author":"A Str\u00f6hle","year":"2018","unstructured":"Str\u00f6hle\u00a0A, Gensichen\u00a0J, Domschke\u00a0K (2018) The diagnosis and treatment of anxiety disorders. Dtsch \u00c4rztebl Int 155:611\u2013620","journal-title":"Dtsch \u00c4rztebl Int"},{"key":"1627_CR38","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.janxdis.2012.02.010","volume":"26","author":"S Taylor","year":"2012","unstructured":"Taylor\u00a0S, Abramowitz\u00a0JS, McKay\u00a0D (2012) Non-adherence and non-response in the treatment of anxiety disorders. J\u00a0Anxiety Disord 26:583\u2013589","journal-title":"J Anxiety Disord"},{"key":"1627_CR39","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1017\/S1092852900022392","volume":"9","author":"M Van Ameringen","year":"2004","unstructured":"Van Ameringen\u00a0M, Mancini\u00a0C, Pipe\u00a0B et\u00a0al (2004) Optimizing treatment in social phobia: a\u00a0review of treatment resistance. CNS spectr 9:753\u2013762","journal-title":"CNS spectr"},{"key":"1627_CR40","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.euroneuro.2011.07.018","volume":"21","author":"HU Wittchen","year":"2011","unstructured":"Wittchen\u00a0HU, Jacobi\u00a0F, Rehm\u00a0J et\u00a0al (2011) The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 21:655\u2013679","journal-title":"Eur Neuropsychopharmacol"},{"key":"1627_CR41","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/da.10106","volume":"17","author":"KA Yonkers","year":"2003","unstructured":"Yonkers\u00a0KA, Bruce\u00a0SE, Dyck\u00a0IR et\u00a0al (2003) Chronicity, relapse, and illness\u2014course of panic disorder, social phobia, and generalized anxiety disorder: findings in men and women from 8\u00a0years of follow-up. Depress Anxiety 17:173\u2013179","journal-title":"Depress Anxiety"},{"key":"1627_CR42","unstructured":"Zwanzger_P, Diemer\u00a0J (2019) Development of virtual reality as an exposure technique. Nervenarzt, PMID: 30715554"},{"key":"1627_CR43","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00115-020-01051-3","volume":"92","author":"P Zwanzger","year":"2021","unstructured":"Zwanzger\u00a0P, Singewald\u00a0N, Bandelow\u00a0B (2021) Pharmacotherapy of anxiety disorders\u2014Guideline-conform treatment and new developments. Nervenarzt 92:433\u2013440","journal-title":"Nervenarzt"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-024-01627-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-024-01627-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-024-01627-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T06:02:37Z","timestamp":1714716157000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00115-024-01627-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,4]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["1627"],"URL":"https:\/\/doi.org\/10.1007\/s00115-024-01627-3","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,4]]},"assertion":[{"value":"2 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"K.\u00a0Domschke war in den letzten drei Jahren Mitglied im \u201eSteering Committee Neurosciences\u201c der Janssen-Cilag GmbH und hat Referentenhonorare von Janssen-Cilag GmbH erhalten. P.\u00a0Zwanzger erhielt in den letzten drei Jahren Vortrags- und Beratungshonorare von Janssen Pharmaceuticals, MedTrix, Hennig, Schwabe, Servier, Sympatient und Neuraxpharm. K.\u00a0Domschke, A.\u00a0Str\u00f6hle und P.\u00a0Zwanzger sind Vorstandsmitglieder der Gesellschaft f\u00fcr Angstforschung (GAF). K.\u00a0Domschke und P.\u00a0Zwanzger sind Mitglieder des Vorstands der Deutschen Gesellschaft f\u00fcr Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN) und des Anxiety Disorders Research Network (ADRN) des European College of Neuropsychopharmacology (ECNP). K.\u00a0Domschke ist Vorstandsmitglied des Freiburger Ausbildungsinstituts f\u00fcr Verhaltenstherapie (FAVT). A.\u00a0Str\u00f6hle ist Leiter des DGPPN-Referats \u201eSportpsychiatrie und -psychotherapie\u201c, P.\u00a0Zwanzger ist Leiter des DGPPN-Referats \u201eDigitale Psychiatrie und Psychotherapie\u201c.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}